This review discusses the current problem of ototoxicity associated with the worldwide use of aminoglycoside antibiotics. Pathology and pathophysiology of cochlear and vestibular damage have long been recognized as a preferential destruction of hair cells beginning in the cochlea with the outer hair cells of the lower turns. This is accompanied by high frequency hearing loss progressing to lower frequencies during and even after treatment with these drugs. A novel hypothesis of the underlying biochemical mechanism is based on the formation of free radicals by an aminoglycoside-iron complex. A protective treatment against aminoglycoside-induced hearing loss by co-administration of iron che lators has been successfully documented in guinea pig. This pharmacological intervention does not change serum levels of aminoglycosides nor their antibacterial efficacy. Since iron chelators are estab lished therapeutic drugs, the proposed treatment should lend itself to clinical application. Amino glycosides, long established for their high efficacy and low cost, may thus continue to play an important role in combating infectious diseases. (Keio J Med 46 (3): 115-119, September 1997) 
Introduction
Drugs used in treatment of infections and diseases frequently have unwanted side effects. Such side effects may range from minor transient discomfort to the patient to potentially severe damage to specific organs and their function. In the latter case, it is imperative to weigh the benefits of a drug against its potential toxicity and to consider alternative treatment. There are, how ever, several classes of drugs with known severe side effects that remain in clinical use because of their com pelling benefits. The aminoglycoside antibiotics fall into this category. The first compound in this class, strepto mycin, was discovered by Waksman in 1944 and was the first successful therapy against tuberculosis.1 Its toxicity to the kidney and the inner ear was described one year later2 but streptomycin itself, and the subsequently introduced aminoglycosides (including neomycin, gentamicin, kanamycin, and sisomicin), have remained in clinical use to this day. In fact, aminoglycosides are such efficacious and inexpensive broad spectrum anti biotics that they are the most commonly used anti biotics worldwide. 
Incidence of Toxicity
The incidence of ototoxicity varies with the type of aminoglycoside and is generally by b generally below 20%. Con trolled clinical studies of gentamicin have determined an incidences of 6 to 16% hearing loss and 9 to 15% impairment of vestibular function.5,6 However, one study even reported an 82% incidence of hearing loss (55 of 67 patients) in tuberculosis patients receiving kanamycin.7 In addition, genetic susceptibility, nutri tional status, noise exposure, gender, age, or pre-existing auditory or vestibular dysfunction have been discussed as risk factors in the ototoxicity of aminoglycosides.
The current problem of aminoglycoside ototoxicity is aggravated in many developing countries where the use of these drugs is widespread primarily for economic reasons and also largely unrestricted. In southeastern China, for example, two-thirds of the cases of deaf mutism were ascribed to the use of aminoglycosides.8,9
Despite these well known side effects, an increased use of aminoglycoside antibiotics can be expected. Op portunistic infections associated with acquired immu nodeficiency syndrome (AIDS) have now resulted in a worldwide resurgence of tuberculosis, which is spread ing to large segments of the general population. The World Health Organization projects tuberculosis to become the most devastating killer disease of the dec ade.10,11 The occurrence of resistant bacteria neces sitates multi-drug regimens, which may include amino glycosides. Given this scenario it seems more urgent than ever to prevent the toxic side effects of amino glycoside antibiotics.
Prevention of Ototoxicity
Attempts to protect against the ototoxic side effects of aminoglycosides through pharmacological interven tion began as soon as these side effects were known. However, such studies remained inconclusive and no treatment has been accepted in the clinic to date (for a summary of early studies, see;12 for a recent discussion, see13). Most attempts at protection employed sulf hydryl compounds, radical scavengers and antioxidants, including traditional medicines and natural prod ucts14-16 but studies frequently reported contradictory findings. For example, while the free radical scavenger WR2721 was found to be effective against kanamycin ototoxicity,17 the scavenger N-acetyl cysteine was inef fective.18 Likewise, glutathione, a natural antioxidant, protected in one study19 but not in another. 20 Such contradictory results may be due to complex mechanisms of toxicity and uncontrolled variables in the experimental design. At least one such confounding variable was elucidated by our laboratory when we showed that the efficacy of glutathione to attenuate gentamicin-induced hearing loss depended on the nutri tional state of the animal. When animals were sick or undernourished, their natural defenses were compro mised and ototoxicity was aggravated. In this case, glu tathione was an effective protectant. In contrast, such dietary supplementation did not change the course of ototoxicity in healthy animals. 21 A further caution in the interpretation of therapeutic intervention is the potential toxicity of the prospective treatment and the interaction of the protectant with serum levels and antibacterial efficacy of the drugs. Examples of these complications can readily be found in previous attempts to ameliorate aminoglycoside toxicity. The compound 2,3-mercaptopropanol, once suggested as an antidote, was later determined to be ototoxic itself.12 In another case, hyperglycemic rats showed dramatic resistance to kanamycin ototoxicity but were found to excrete the drug considerably more rapidly than normal animals.22 Finally, poly-L-aspartate had been extensively studied as a protectant against nephrotoxicity and was also found to inhibit the co chlear toxicity of gentamicin in guinea pig.23 This com pound, however, also eliminated the antibacterial activity of gentamicin.24
Mechanism of Ototoxicity
While such confounding factors may have contri buted to inconclusive results in the past, a rational therapy was also hampered by the lack of a viable hypothesis of aminoglycoside ototoxicity. This recently changed when our laboratory was able to delineate a hypothesis on the basis of extensive in vitro and in vivo studies. The key to this hypothesis is the demonstration that aminoglycosides act as iron chelators and promote the formation of reactive oxygen species (free radi cals).25,26 The development of this theory was prompted by the initially surprising finding that aminoglycosides by themselves are not toxic to isolated hair cells27 but require prior activation to become cytotoxic.28,29 An "activated" gentamicin , capable of catalyzing oxidation/ reduction reactions was then found in the form of a gentamicin-iron chelate.25 Metal binding is a known mechanism in both drug effectiveness and toxicity. If iron is the chelated metal, the resulting complex will promote free-radical reactions. For example, the anti neoplastic glycopeptide bleomycin requires the pres ence of iron for its therapeutic activity as a deoxy ribonucleic acid (DNA) cleaving agent . 30 Therapeutic Prevention
Based on this hypothesis we can propose an effective therapeutic intervention against aminoglycoside ototox icity. Since different radical species may be formed, no single radical scavenger may be completely effective. Therefore, preventing the formation of the initial aminoglycoside-iron complex may be the most promis ing intervention. This can be accomplished by the administration of other iron chelators which compete with aminoglycosides for available iron and thereby reduce the concentration of the aminoglycoside-iron complex. Indeed, co-administration of deferoxamine (DFO) and dihydroxybenzoic acid (DHB), both well known iron chelators, drastically reduced gentamicin ototoxicity in guinea pig.37 When mannitol, a hydroxyl radical scavenger and weak iron chelator, was addi tionally administered, the gentamicin-induced threshold shift was essentially eliminated. 38 The effectiveness of this treatment is not limited to gentamicin but extends to other aminoglycosides and to both their vestibular and cochlear damage.38,39 Essential for prospective clinical application, the serum level of gentamicin and the antibacterial activity of gentamicin were not influ enced by the co-administered drugs.
It is interesting in this context to consider a recent suggestion that N-methyl-D-aspartate (NMDA) an tagonists limit aminoglycoside-induced hearing loss.40 Such a suggestion apparently fits well with documented polyamine-aminoglycoside antagonism in many sys tems,41,42 including competition for uptake in the inner ear43 and inhibition of cochlear ornithine decarbox ylase. 44 However, in the study of NMDA antagonists, the two protective compounds dizocilpine and ifenprodil were given as their maleate and tartrate salts, respec tively. Both maleate and tartrate have metal chelating properties45 and, therefore, the suggested protection may be due to metal chelation rather than polyamine 
